Diabetic dyslipidemia.
By the year 2025, there will be more than 300 million type 2 diabetes sufferers worldwide. This epidemic will be followed by a wave of cardiovascular disease. Diabetes is in fact a serious vascular disease with poor prognosis, and not only a disease characterized by elevated blood glucose. If adequate attention were paid to this, it would be much easier to relieve the burden of cardiovascular disease in type 2 diabetes patients. One important cardiovascular risk factor in type 2 diabetic people is dyslipidemia. This is characterized by low HDL-cholesterol, high serum VLDL-triglycerides, and a preponderance of small, dense LDL. Even slight elevations of LDL-cholesterol in type 2 diabetic patients are associated with a substantial increase in cardiovascular risk. The composition of lipid particles in diabetic dyslipidemia is more atherogenic than in dyslipidemia in general. This means in turn that normal lipid concentrations are more atherogenic in diabetic than in non-diabetic patients. Retrospective analyses show that, in terms of protection from cardiovascular endpoints, the benefit of lipid lowering in type 2 diabetic patients is at least as great as in the non-diabetic population. Lowering of LDL-cholesterol is a very attractive target for the reduction of coronary heart disease in type 2 diabetic people.
Taskinen
Marja-Riitta
MR
University of Helsinki, Meilahti Hospital, Helsinki, Finland. mataskin@helsinki.fi
D001053:Apolipoproteins / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000378:metabolism*; D003327:Coronary Disease / Q000150:complications* / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control; D008148:Lovastatin / Q000627:therapeutic use; D015995:Prevalence; D012307:Risk Factors
D001053:Apolipoproteins; D008078:Cholesterol, LDL; D008148:Lovastatin